Head-To-Head Comparison: DENTSPLY SIRONA (XRAY) versus Alliqua BioMedical (NASDAQ:ALQA)
DENTSPLY SIRONA (NASDAQ: XRAY) and Alliqua BioMedical (NASDAQ:ALQA) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, dividends, valuation, earnings, profitabiliy and analyst recommendations.
This table compares DENTSPLY SIRONA and Alliqua BioMedical’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings and Valuation
This table compares DENTSPLY SIRONA and Alliqua BioMedical’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|DENTSPLY SIRONA||$3.87 billion||3.86||$820.80 million||$1.55||42.01|
|Alliqua BioMedical||$18.88 million||0.93||-$20.24 million||($0.96)||-0.40|
DENTSPLY SIRONA has higher revenue and earnings than Alliqua BioMedical. Alliqua BioMedical is trading at a lower price-to-earnings ratio than DENTSPLY SIRONA, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of current ratings for DENTSPLY SIRONA and Alliqua BioMedical, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
DENTSPLY SIRONA presently has a consensus price target of $67.60, suggesting a potential upside of 3.82%. Alliqua BioMedical has a consensus price target of $1.42, suggesting a potential upside of 272.81%. Given Alliqua BioMedical’s stronger consensus rating and higher probable upside, analysts plainly believe Alliqua BioMedical is more favorable than DENTSPLY SIRONA.
Insider and Institutional Ownership
94.9% of DENTSPLY SIRONA shares are owned by institutional investors. Comparatively, 26.2% of Alliqua BioMedical shares are owned by institutional investors. 2.0% of DENTSPLY SIRONA shares are owned by company insiders. Comparatively, 15.2% of Alliqua BioMedical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Volatility and Risk
DENTSPLY SIRONA has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500. Comparatively, Alliqua BioMedical has a beta of 0.97, suggesting that its stock price is 3% less volatile than the S&P 500.
DENTSPLY SIRONA pays an annual dividend of $0.35 per share and has a dividend yield of 0.5%. Alliqua BioMedical does not pay a dividend. DENTSPLY SIRONA pays out 22.6% of its earnings in the form of a dividend.
DENTSPLY SIRONA beats Alliqua BioMedical on 11 of the 15 factors compared between the two stocks.
About DENTSPLY SIRONA
DENTSPLY SIRONA Inc. is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies. The dental industry encompasses the diagnosis, treatment and prevention of disease and ailments of the teeth, gums and supporting bone. Its principal dental product categories are dental consumable products, dental laboratory products, dental specialty products and dental equipment. Additionally, its consumable medical device products are used for urological and surgical applications. These products are produced by the Company in the United States and internationally and are distributed throughout the world under various brand names, including ANKYLOS, AQUASIL ULTRA, ARTICADENT, ATLANTIS, CALIBRA, CAULK, CAVITRON, CELTRA, DELTON, DENTSPLY, DETREY and DYRACT.
About Alliqua BioMedical
Alliqua BioMedical, Inc. is a provider of advanced wound care solutions. The Company’s businesses include advanced wound care and contract manufacturing. The Company operates through its subsidiaries, such as AquaMed Technologies, Inc. and Choice Therapeutics, Inc. The Company is engaged in developing a suite of advanced wound care solutions that will enable surgeons, clinicians and wound care practitioners to address the challenges in chronic and acute wounds. The Company utilizes hydrogel technology through which hydrogels are manufactured by introducing a hydrophilic polymer into water to create a feed mix. The Company’s commercial wound care portfolio consists of over four product categories, such as Human Biologics; Antimicrobial Protection; Exudate Management and Contract Manufacturing. Human Biologics include BIOVANCE and Extracellular Matrix (ECM). Under Antimicrobial Protection, the Company offers TheraBond 3D Antimicrobial Barrier Systems and SilverSeal.
Receive News & Ratings for DENTSPLY SIRONA Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA Inc. and related companies with MarketBeat.com's FREE daily email newsletter.